Artikel
Diagnosis of recurrent gliomas: Positron emission tomography [18F]Fluor-O-Ethyl-Tyrosine versus MRI
Diagnose von Gliomrezidiven: [18F]Fluor-O-Ethyl-Tyrosin-Positronenemissionstomographie versus MRT
Suche in Medline nach
Autoren
Veröffentlicht: | 23. April 2004 |
---|
Gliederung
Text
Objective
Tumor recurrence appears in a large amount of patients suffering from glioma. Due to the variety of presently accessible modalities for treatment of gliomas, it has become more difficult to differentiate tumor recurrence from therapy associated contrast enhancement. In order to increase the diagnostic accuracy in the detection of tumor recurrence in glioma patients, we performed FET-PET in addition to MRI and compared the diagnostic value of these two modalities.
Methods
MRI findings of 45 multimodally treated glioma patients (1 pilocytic astrocytoma, 8 astrocytomas WHO grade II, 1 oligoastrocytoma WHO grade II, 1 oligodendroglioma WHO grade II, 11 anaplastic astrocytomas, 1 oligodendroglioma WHO grade III, and 22 glioblastoma multiforme WHO grade IV) were correlated with findings of FET-PET in these patients. Final diagnosis was verified by biopsies (21 patients) or clinical follow-up (24 patients).
Results
Sensitivity of FET-PET was 100%, specificity was 92,9%. The positive predictive value was 96,9%, the negative predictive value 100%. For MRI, sensitivity was 93,5%, specificity was 50%. The positive predictive value was 80,6%, the negative value was 77,8%.
Conclusions
Statistical analysis showed that in clinical follow-up of multimodally treated glioma patients discrimination between tumor recurrence and therapy associated contrast enhancement is not sufficient by MRI alone. More accurate diagnosis will be achieved by the additional performance of FET-PET examination in the clinical aftercare of these patients.